Research Frontiers

Chapter 21: Research Frontiers — Where Prostate Cancer Treatment Is Heading

Chapter Opening: David's Story

David was 68 when his prostate cancer stopped responding to hormone therapy and chemotherapy. His PSA was climbing, and his oncologist told him that standard options were running out. But then his doctor mentioned a clinical trial testing a new type of treatment — a radioactive molecule that could find and destroy prostate cancer cells anywhere in the body. David enrolled, and within three months, his PSA dropped by over 90%. "I felt like I was part of something bigger than myself," he said. "The treatment that helped me started because someone before me said yes to a trial." David's story is not unique. Every treatment discussed in this book — surgery, radiation, hormone therapy, chemotherapy — was once experimental. Today's clinical trials are tomorrow's standard of care.

Part 1: Why Research Matters

Every treatment you have read about in this book was once an experiment. Radical prostatectomy, radiation therapy, hormone therapy, PSMA-targeted therapy — all began as ideas tested in clinical trials before becoming standard care.

The pace of progress has accelerated dramatically. More advances in prostate cancer treatment have occurred in the last 15 years than in the previous 50. New drugs, new imaging techniques, new radiation technologies, and entirely new categories of treatment — like radioligand therapy and immunotherapy — have transformed what is possible.

Patients who participate in clinical trials are not just receiving treatment; they are contributing to knowledge that will help future patients. Every advance started because someone said "yes" to a trial.

"Promising" Does Not Mean "Proven"

When you read a headline about a cancer breakthrough, it is important to understand where that discovery falls in the research pipeline:

• Preclinical research: Laboratory and animal studies. Most discoveries at this stage never reach patients.
• Phase 1 trials: First tests in humans. Small groups (10–30 patients). The goal is to find a safe dose, not to cure cancer.
• Phase 2 trials: Larger groups (30–100+ patients). The goal is to see if the treatment works and to learn more about side effects.
• Phase 3 trials: Large studies (hundreds to thousands of patients) comparing the new treatment to the current standard. This is the evidence needed for FDA approval.
• FDA approval: The treatment becomes available for routine clinical use.

This pipeline typically takes 10–15 years from laboratory to clinic. Only about 5–10% of drugs that enter clinical trials ultimately receive FDA approval.¹

SECTION A: RADIATION THERAPY FRONTIERS

Part 2: FLASH Radiotherapy

Conventional radiation therapy delivers its dose over several minutes. FLASH radiotherapy delivers the same dose in a fraction of a second — at dose rates exceeding 40 Gy per second, compared to the standard 0.01–0.03 Gy per second.²

Why does speed matter? Preclinical studies in animals have shown that this ultra-fast delivery produces what scientists call the "FLASH effect" — it appears to damage cancer cells just as effectively as conventional radiation, but causes significantly less harm to surrounding normal tissues.² ³

A treatment planning study specifically evaluating prostate cancer found that FLASH radiotherapy showed positive "net sparing" — meaning the protective FLASH effect on normal tissues outweighed any increased toxicity from the higher doses per fraction. Prostate and breast cancers appeared to be particularly well-suited tumor sites for FLASH, while head-and-neck and brain tumors did not show the same benefit.⁴

The first-in-human randomized trial of FLASH proton radiotherapy focused on patients with bone metastases and established feasibility, showing similar efficacy and safety to conventional dose-rate photon radiotherapy.² However, FLASH radiotherapy for prostate cancer specifically has not yet entered human clinical trials. Several technical challenges remain, including optimizing treatment planning and delivery systems for clinical use.³

Bottom line: FLASH is one of the most exciting radiation innovations on the horizon, but it remains years away from routine clinical use for prostate cancer.

Part 3: MRI-Guided Radiation (MR-Linac)

Imagine if your radiation therapist could see your prostate in real time — not with X-rays, but with MRI — during every single treatment. That is exactly what MRI-guided radiation therapy (MRgRT) does.

An MR-Linac combines a magnetic resonance imaging (MRI) scanner with a radiation treatment machine (linear accelerator) in one device. This allows the treatment team to:

• See the prostate clearly during each treatment session, without the need for implanted markers (fiducials)
• Adapt the treatment plan daily based on the actual position and shape of the prostate, bladder, and rectum that day
• Track the prostate in real time during treatment delivery, automatically pausing the beam if the prostate moves out of position

The landmark MIRAGE randomized clinical trial compared MRI-guided SBRT to CT-guided SBRT for prostate cancer. At two years, MRI guidance significantly reduced late grade 2 or higher genitourinary toxicity (27% vs. 51%) and gastrointestinal toxicity (1.4% vs. 9.5%).⁵ Patient-reported bowel function and sexual function were also significantly better preserved with MRI guidance.⁵

A study of 150 patients treated with MRI-guided SBRT (36.25 Gy in 5 fractions) reported estimated 5-year biochemical recurrence-free survival of 81.8%, with no acute or late grade 3 or higher toxicity observed.⁶ Notably, 88% of treatment fractions required daily plan adaptation — meaning the anatomy was different enough from the original plan that adjustments were needed on most days.⁷

MRI-guided radiation is also being used for reirradiation of locally recurrent prostate cancer after prior radiation therapy — a situation where precision is critical. A prospective registry study of 108 patients treated with MRI-guided stereotactic reirradiation reported encouraging biochemical control with low rates of severe toxicity.⁸

Bottom line: MRI-guided radiation represents a significant advance in treatment precision. It is available at a growing number of centers and is particularly valuable for SBRT delivery and reirradiation scenarios.

Part 4: Ultra-Hypofractionation and SBRT Advances

As discussed in Chapter 10, SBRT delivers the entire radiation course in just 5 treatments instead of 20–44. The evidence supporting this approach continues to strengthen.

The PACE-B phase 3 trial randomized 874 men with low- and intermediate-risk prostate cancer to either 5-fraction SBRT (36.25 Gy) or conventional/moderately hypofractionated radiotherapy. At 5 years, freedom from biochemical or clinical failure was 95.8% for SBRT and 94.6% for conventional radiotherapy — confirming that SBRT was noninferior.⁹ The hazard ratio of 0.73 fell well below the prespecified noninferiority margin of 1.45.⁹

The NCCN guidelines now state that ultra-hypofractionation has been demonstrated to be noninferior to both moderate hypofractionation and conventional fractionation, and that conventionally fractionated radiotherapy is no longer preferred for localized prostate cancer.¹⁰

Current research is pushing further:

• The PR24 trial is comparing pelvic SBRT (5 fractions, 40 Gy to prostate and 25 Gy to pelvis) to conventional radiation plus brachytherapy boost in unfavorable-risk patients — testing whether SBRT can replace even the most intensive radiation approaches.¹¹
• Studies are investigating whether SBRT can be safely combined with elective pelvic nodal irradiation for higher-risk disease.¹¹

Part 5: Oligometastasis-Directed Radiation

One of the most exciting concepts in prostate cancer is the idea that when cancer has spread to only a few spots (oligometastatic disease), treating those spots directly with radiation might delay or even prevent the need for lifelong systemic therapy.

Two landmark randomized phase 2 trials established this concept:

• STOMP trial: 62 patients with up to 3 metastases detected on choline PET. Metastasis-directed therapy (MDT) extended ADT-free survival from 13 months (observation) to 21 months.¹²
• ORIOLE trial: 54 patients randomized to SBRT or observation using PSMA PET imaging. Progression at 6 months was dramatically lower with SBRT (19% vs. 61%). Critically, patients who had all PSMA-positive disease treated had even better outcomes (new lesion rate 16% vs. 63%).¹²

A pooled analysis of both trials with over 4 years of follow-up confirmed a sustained benefit: median progression-free survival was significantly prolonged with MDT (HR 0.44, p 0.001).¹²

The WOLVERINE individual patient data meta-analysis — the most comprehensive analysis to date, combining six randomized trials and 472 patients — confirmed that MDT improved progression-free survival (HR 0.44), radiographic progression-free survival (HR 0.60), and castration resistance-free survival across oligometastatic prostate cancer subtypes.¹³

More recent trials are exploring whether combining MDT with short-course systemic therapy produces even better results:

• EXTEND trial: Showed that intermittent ADT plus MDT improved progression-free survival, radiographic progression-free survival, and castration resistance-free survival compared to ADT alone.¹⁴
• RADIOSA trial: Compared SBRT alone to SBRT plus 6 months of ADT in oligorecurrent prostate cancer.¹⁵

Several phase 3 trials are ongoing, including START-MET and PRESTO, which will provide the definitive evidence needed to establish MDT as standard of care.¹⁶

Bottom line: The evidence for treating oligometastatic prostate cancer with radiation is growing rapidly. While not yet universally considered standard of care, many experts now offer MDT to appropriately selected patients, and clinical trials are actively enrolling.

Part 6: Proton Therapy and Other Advances

Proton therapy uses protons instead of X-rays to deliver radiation. Protons have a unique physical property — they deposit most of their energy at a specific depth (the "Bragg peak") and then stop, potentially reducing radiation dose to tissues beyond the target.

The NCCN guidelines state that photon and proton radiotherapy are acceptable forms of external beam radiation and appear to have similar outcomes regarding toxicity, quality of life, and tumor control. However, potential financial toxicity should be discussed with patients, as proton therapy is significantly more expensive.¹⁰

Research frontiers in proton therapy include:

• FLASH protons: Combining the ultra-fast delivery of FLASH with the precision of protons
• Spot-scanning improvements: More precise dose delivery within the prostate
• Comparative trials: Ongoing studies comparing proton SBRT to photon SBRT

Other radiation innovations under investigation include:

• Spacer and fiducial innovations for better organ separation and tracking
• AI-driven auto-contouring that draws treatment volumes in seconds instead of hours
• AI-optimized treatment planning and real-time quality assurance

SECTION B: SURGICAL FRONTIERS

Part 7: Robotic Surgery Innovations

Robotic-assisted radical prostatectomy has become the dominant surgical approach in many countries. The next generation of robotic platforms is pushing the boundaries further:

• Single-port robotic surgery: Instead of 4–6 small incisions, the entire operation is performed through a single incision, typically at the navel. This may reduce pain and improve cosmetic outcomes.
• Micro-robotic instruments: Smaller, more flexible instruments with haptic feedback — allowing the surgeon to "feel" tissue resistance, which current robotic systems lack.
• Improved 3D visualization: Higher-resolution cameras and augmented reality overlays.

Part 8: Image-Guided and Augmented Surgery

• Augmented reality: MRI or PET images are overlaid onto the surgeon's view during the operation, helping identify cancer boundaries that are invisible to the naked eye.
• Fluorescence-guided surgery: Special dyes that make cancer cells glow under specific light wavelengths, helping the surgeon see and remove cancer more completely.
• Real-time margin assessment: Technologies that can determine whether all cancer has been removed before the operation is finished, potentially reducing the rate of positive surgical margins.

Part 9: Nerve-Sparing and Functional Innovations

Preserving the nerves responsible for erections and urinary control remains one of the greatest challenges in prostate surgery. Research frontiers include:

• Advanced nerve mapping using specialized imaging before and during surgery
• Nerve grafting and regeneration research — experimental techniques to repair damaged nerves
• Improved understanding of the precise anatomy of the neurovascular bundles, leading to more refined nerve-sparing techniques

Part 10: Focal Surgery and Lymph Node Innovations

• Focal surgery: Removing only the cancerous portion of the prostate rather than the entire gland. This is still considered experimental and is best pursued within clinical trials.
• Sentinel lymph node mapping: Using fluorescent or radioactive tracers to identify the first lymph nodes that drain the prostate, potentially allowing surgeons to remove fewer lymph nodes while still accurately staging the cancer.

SECTION C: SYSTEMIC THERAPY FRONTIERS

Hormonal Therapies

Part 11: Next-Generation Androgen Receptor Targeting

Current hormone therapies like enzalutamide, abiraterone, and darolutamide work by blocking the androgen receptor (AR) or reducing androgen production. But cancer cells can develop resistance — often by producing extra copies of the AR gene or by mutating the receptor so drugs no longer block it.

Next-generation approaches aim to overcome this resistance:

• Androgen receptor degraders (ARDs): Instead of just blocking the receptor, these drugs destroy it entirely. Several ARDs are in clinical trials for mCRPC.
• Bipolar androgen therapy (BAT): A counterintuitive approach that cycles patients between high-dose testosterone and standard hormone suppression. The theory is that flooding cancer cells with testosterone after prolonged deprivation can cause DNA damage and cell death, and may re-sensitize tumors to standard hormone therapies. Early clinical trials have shown promising results in selected patients.

Immunotherapy

Part 12: Checkpoint Inhibitors and Combinations

Prostate cancer has historically been resistant to immunotherapy because it is considered an immunologically "cold" tumor — meaning it does not attract many immune cells and has few mutations for the immune system to recognize.¹⁷

However, there are important exceptions:

• MSI-high/dMMR tumors: Pembrolizumab is FDA-approved for any solid tumor that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), including prostate cancer. This applies to approximately 2–5% of advanced prostate cancers.¹⁸
• TMB-high tumors: Pembrolizumab is also approved for tumors with high tumor mutational burden (TMB-H ≥10 mutations/megabase).¹⁸

Research is actively exploring how to make prostate cancer more responsive to immunotherapy:

• Combining checkpoint inhibitors with radiation therapy (which can trigger immune responses)
• Combining with PARP inhibitors or hormone therapy
• Manipulating the tumor microenvironment to convert "cold" tumors to "hot" ones

Part 13: Bispecific Antibodies — A New Class of Immunotherapy

Bispecific antibodies are engineered molecules that can grab onto two different targets simultaneously — typically one arm grabs a protein on the cancer cell, and the other arm grabs a T cell (an immune cell), physically bringing them together so the T cell can kill the cancer.

Xaluritamig (AMG 509) is the most advanced bispecific antibody in prostate cancer. It targets STEAP1 (a protein found on most prostate cancer cells) and CD3 (on T cells).

In its first-in-human study of 97 patients with heavily pretreated mCRPC:¹⁹

• 49% of patients achieved a PSA decline of 50% or more
• At target doses of 0.75 mg or higher: 59% PSA50 response and 41% objective response rate (tumor shrinkage on imaging)
• The most common side effect was cytokine release syndrome (CRS) in 72% of patients, mostly during the first cycle and mostly mild

More recent data combining xaluritamig with abiraterone in chemotherapy-naïve mCRPC showed confirmed PSA50 response rates of 58% and objective response rates of 43%, with a median radiographic progression-free survival of 10.5 months.²⁰

Xaluritamig is now being tested in:

• XALute: A phase 3 trial comparing xaluritamig to cabazitaxel or second-line hormone therapy in post-taxane mCRPC²¹
• XALience: A phase 3 trial evaluating xaluritamig plus abiraterone in chemotherapy-naïve mCRPC²⁰
• A phase 1b trial in patients with biochemical recurrence only (no metastases on conventional imaging) — testing whether this treatment can work in much earlier disease²²

Part 14: Cancer Vaccines — Next Generation

Sipuleucel-T (Provenge) was the first cancer vaccine approved for prostate cancer (2010). While it showed a modest survival benefit, the field has evolved significantly:

• Personalized neoantigen vaccines: These are custom-made vaccines based on the unique mutations in your specific cancer. Your tumor is sequenced, the most immunogenic mutations are identified, and a vaccine is manufactured specifically for you.
• mRNA vaccine platforms: Using the same technology that produced COVID-19 vaccines, researchers are developing mRNA-based cancer vaccines that teach the immune system to recognize prostate cancer proteins.
• Combination strategies: Vaccines combined with checkpoint inhibitors may be more effective than either alone, as the vaccine primes the immune response and the checkpoint inhibitor removes the "brakes."

Part 15: CAR-T Cell Therapy

CAR-T (Chimeric Antigen Receptor T-cell) therapy has revolutionized the treatment of certain blood cancers like leukemia and lymphoma. The concept is elegant: doctors take your own T cells (immune cells) from your blood, genetically engineer them in a laboratory to recognize a specific protein on cancer cells, multiply them into billions, and infuse them back into your body to hunt and destroy cancer.

Applying CAR-T to prostate cancer — a solid tumor — has been much more challenging than in blood cancers. The main obstacles include:²³ ²⁴

• The immunosuppressive tumor microenvironment of prostate cancer
• Antigen heterogeneity — not all cancer cells express the same target proteins
• Difficulty getting CAR-T cells to infiltrate solid tumors
• Toxicity, including cytokine release syndrome

The most advanced CAR-T program in prostate cancer is P-PSMA-101, which targets PSMA. In a phase 1 trial of 33 patients with mCRPC:²⁵

• 21% achieved a PSA decline of 50% or more
• 61% had stable disease, with 21% maintaining stability for 3 months or more
• Two patients achieved remissions lasting over 12 months with PSA declines greater than 90%
• However, cytokine release syndrome occurred in 61%, and the safety switch had to be activated in 24% of patients, including one fatal toxicity

A systematic review and meta-analysis of seven CAR-T trials in prostate cancer (69 patients total) reported a pooled objective response rate of 39% and PSA50 response rate of 48%.²⁶

Other CAR-T targets under investigation include STEAP1, PSCA, KLK2, and STEAP2.²⁷ Next-generation approaches include "armored" CAR-T cells that secrete immune-stimulating molecules, dual-target CARs that recognize two proteins simultaneously, and iPSC-derived CAR-T cells that could be manufactured "off the shelf" rather than custom-made for each patient.²⁴

Bottom line: CAR-T therapy for prostate cancer shows early promise but remains experimental. Durable responses are rare, and toxicity is significant. Ongoing research is focused on improving efficacy and safety.

Targeted Therapies

Part 16: PARP Inhibitor Combinations and Expansion

PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) are already approved for prostate cancer patients with specific DNA repair gene mutations (discussed in Chapter 12). Research frontiers include:

• Expanding beyond BRCA: Testing PARP inhibitors in patients with other DNA repair mutations such as ATM, PALB2, CHEK2, and CDK12
• Combination strategies: PARP inhibitors combined with hormone therapy (already approved for BRCA-mutated mCRPC), immunotherapy, or radiation therapy
• Overcoming PARP resistance: Understanding why cancers become resistant and developing strategies to re-sensitize them

Part 17: Novel Targeted Pathways and Antibody-Drug Conjugates

• AKT inhibitors (ipatasertib, capivasertib): Target the PI3K/AKT pathway, which is altered in approximately 40–50% of mCRPC cases
• Antibody-drug conjugates (ADCs): Think of these as "guided missiles" — an antibody that finds the cancer cell is attached to a powerful chemotherapy drug. The antibody delivers the chemotherapy directly to the cancer cell, sparing normal tissues. Several ADCs targeting STEAP1 and other prostate cancer proteins are in clinical trials.²⁸

SECTION D: THERANOSTICS — THE "SEE IT AND TREAT IT" REVOLUTION

Part 18: What Is Theranostics?

Theranostics is one of the most exciting concepts in modern cancer medicine, and prostate cancer is leading the way. The word combines "therapeutics" and "diagnostics" — using the same molecule for both finding and treating cancer.

Here is how it works:

1. Diagnosis: A PSMA-targeting molecule is attached to a radioactive tracer (like gallium-68) and injected into your blood. It travels throughout your body and sticks to prostate cancer cells wherever they are. A PET scan then lights up every cancer deposit.
2. Treatment: The same PSMA-targeting molecule is attached to a different radioactive isotope — one that emits radiation capable of killing cells (like lutetium-177). When injected, it finds and irradiates cancer cells from the inside.

This "see it and treat it" approach is uniquely advanced in prostate cancer compared to other cancers, because PSMA is expressed on the vast majority of prostate cancer cells.

Lutetium-177 PSMA-617 (Pluvicto) is already FDA-approved for mCRPC (discussed in Chapter 12). The research frontier is focused on what comes next.

Part 19: Next-Generation Radiopharmaceuticals — Alpha Emitters

Lutetium-177 emits beta particles — relatively low-energy radiation that travels a few millimeters in tissue. The next generation uses alpha emitters — particles that are much more energetic and travel only a fraction of a millimeter, delivering devastating damage to cancer cells while sparing nearby normal tissue.

Actinium-225 (Ac-225) PSMA is the most studied alpha emitter:

• A meta-analysis of 18 studies involving 1,155 patients found that 65% achieved a PSA decline of 50% or more, with progression-free survival ranging from 3 to 15 months and overall survival from 8 to 31 months.²⁹
• The AcTION phase 1 trial — the first prospective dose-escalation study of Ac-225-PSMA-617 — treated 101 patients across three groups. In chemotherapy/ARPI-naïve patients, the PSA50 response rate was an impressive 85.2%, and PSA90 was 81.5%. No dose-limiting toxicities were observed, and the recommended phase 2 dose was established at 10 MBq.³⁰
• Importantly, Ac-225 PSMA showed activity even in patients whose cancer had progressed after lutetium-177 PSMA therapy, with PSA50 response rates of 52.5%.³⁰
• Two phase 3 trials — AcTFirst and PSMAcTION — are now recruiting to definitively establish the role of Ac-225 PSMA.³⁰

The main side effects of Ac-225 PSMA include:³⁰ ³¹

• Dry mouth (xerostomia): Occurs in over 90% of patients because salivary glands also express PSMA. This is the most significant quality-of-life concern.
• Anemia: Grade 3 or higher in approximately 15–18% of patients
• Fatigue

Other alpha emitters under investigation include thorium-227 and lead-212.

Part 20: Radiopharmaceutical Combinations

Rather than using radiopharmaceuticals alone, researchers are testing combinations:

• Lu-177 PSMA + chemotherapy (e.g., TheraP2 trial)
• Lu-177 PSMA + PARP inhibitors (e.g., LuPARP trial)
• Lu-177 PSMA + immunotherapy (e.g., PRINCE trial)
• Ac-225/Lu-177 PSMA tandem therapy: Combining both isotopes to leverage the complementary advantages of alpha and beta emitters. A meta-analysis of 323 patients treated with tandem therapy showed 47% achieved PSA50 decline, with a median overall survival of 11.8 months and low rates of severe toxicity.³²

Part 21: Beyond PSMA Targets

Not all prostate cancers express PSMA. Approximately 10–20% of mCRPC patients are ineligible for PSMA-targeted therapy due to low or absent PSMA expression, and these patients tend to have particularly poor outcomes.³³

New theranostic targets under development include:³³

• STEAP1: Already being targeted by bispecific antibodies and ADCs; PET tracers are in development
• KLK2 (kallikrein-2): An actinium-225-labeled KLK2 agent (JNJ-69086420) has shown deep PSA responses in early trials
• PSCA, B7-H3, GRPR (bombesin receptor), CD46: PET tracers are under development for most of these
• FAPI (fibroblast activation protein inhibitor): Targets the tumor stroma rather than cancer cells directly
• DLL3: A target for neuroendocrine prostate cancer, a particularly aggressive variant

SECTION E: IMAGING FRONTIERS

Part 22: Next-Generation PET Tracers

PSMA PET has transformed prostate cancer imaging, but the field continues to evolve:

• Novel PSMA tracers with improved sensitivity and image quality
• Non-PSMA tracers for PSMA-negative disease (FAPI, bombesin-based tracers)
• Total-body PET scanners: These can image the entire body simultaneously with lower radiation doses and faster scan times
• FDG PET: While not useful for typical prostate cancer, FDG PET can be valuable in aggressive variants like neuroendocrine prostate cancer and some castration-resistant cases

Part 23: Advanced MRI and Ultrasound

• Whole-body MRI: Screening and staging the entire body without radiation exposure. Being studied as an alternative to PET/CT in some settings.
• AI-enhanced MRI interpretation: Algorithms that standardize PI-RADS scoring and reduce variability between radiologists
• Abbreviated MRI protocols: Faster, cheaper scans that may make MRI screening more practical
• 29 MHz micro-ultrasound: Provides near-MRI resolution in the office setting, potentially allowing real-time cancer detection during biopsy without the need for a separate MRI
• PET/MRI hybrid scanners: Combining the metabolic information of PET with the anatomic detail of MRI in a single scan

Part 24: Imaging for Treatment Response

• Molecular imaging to assess whether treatment is working — potentially detecting response or resistance before PSA changes
• Early response markers on PET that may predict long-term outcomes after just a few weeks of treatment
• MRI assessment after SBRT: A study showed that MRI complete response at 6 months after MRI-guided SBRT correlated with PSA kinetics and may serve as an early indicator of treatment success³⁴

SECTION F: PATHOLOGY AND BIOMARKER FRONTIERS

Part 25: Artificial Intelligence and Digital Pathology

When a pathologist looks at your biopsy under a microscope, they are making a subjective judgment about the Gleason grade — how aggressive the cancer looks. Different pathologists can assign different grades to the same biopsy, and this variability can affect treatment decisions.

AI is changing this. Deep learning algorithms can now:

• Detect prostate cancer on biopsy slides with sensitivity exceeding 99%³⁵
• Assign Gleason grades with agreement comparable to expert uropathologists. The PANDA challenge — the largest digital pathology competition ever, involving 1,290 developers and over 10,600 digitized biopsies — showed that AI algorithms achieved pathologist-level performance across international validation sets (quadratic weighted kappa of 0.862–0.868).³⁶
• Improve pathologist performance: When pathologists used AI assistance, their agreement with expert uropathologists increased, and their average slide examination time decreased from 55.7 to 36.8 seconds per case.³⁷
• Predict outcomes directly from standard biopsy slides — potentially providing Decipher-like prognostic information without the need for expensive genomic testing³⁸
• Identify features invisible to the human eye, such as cribriform patterns, perineural invasion, and molecular alterations

AI pathology tools are also being validated in diverse populations, including cohorts with approximately 50% Black patients, to ensure equitable performance across racial groups.³⁸

What this means for you: AI will not replace your pathologist, but it will make pathology more consistent, faster, and potentially more informative. Think of it as giving your pathologist a powerful second opinion on every slide.

Part 26: Liquid Biopsies and Circulating Tumor DNA (ctDNA)

A liquid biopsy is a blood test that can detect cancer-related molecules circulating in your bloodstream — no needle in the prostate required.

Circulating tumor DNA (ctDNA) is the most clinically advanced liquid biopsy analyte. When cancer cells die, they release fragments of their DNA into the blood. By analyzing these fragments, doctors can:

• Detect cancer mutations without a tissue biopsy — particularly useful when a metastatic biopsy is unsafe or unfeasible. The NCCN guidelines already recommend ctDNA as an option in this situation.³⁹
• Monitor treatment response in real time — ctDNA levels can rise or fall faster than PSA in some cases
• Detect recurrence earlier than PSA — tumor-informed ultra-sensitive assays can identify minimal residual disease after surgery or radiation
• Identify resistance mechanisms — understanding why a treatment stopped working

A meta-analysis of 13 studies including 18,575 patients found that detectable ctDNA was associated with significantly worse progression-free survival (HR 1.65) and overall survival (HR 2.20) compared to undetectable ctDNA.⁴⁰

Real-world data from the FoundationOne Monitor pilot showed that ctDNA was detectable in 53% of prostate cancer patients on therapy, with longitudinal changes observed in 67% of patients — supporting its potential utility for monitoring treatment response and emerging resistance.⁴¹

Important caution: ctDNA testing has limitations. In early-stage or low-volume disease, ctDNA levels may be too low to detect. Additionally, a phenomenon called clonal hematopoiesis of indeterminate potential (CHIP) — mutations in blood cells unrelated to cancer — can cause false-positive results, particularly for genes like BRCA, ATM, and CHEK2.³⁹ ⁴²

Circulating tumor cells (CTCs) are intact cancer cells found in the blood. While they can be counted and analyzed, detection rates in localized prostate cancer are low (10–11%), limiting their current clinical utility in early disease.⁴²

Part 27: Multi-Cancer Early Detection Tests

Imagine a single blood test that could screen for dozens of cancers at once. Multi-cancer early detection (MCED) tests aim to do exactly that.

The Galleri test (by GRAIL) is the most studied MCED test. It analyzes methylation patterns in cell-free DNA to detect cancer signals and predict the tissue of origin. It claims to screen for over 50 cancer types.⁴³

Key findings:⁴³ ⁴⁴ ⁴⁵

• Specificity: Very high at 99.5% (very few false positives)
• Overall sensitivity: Moderate at 51.5%, with pronounced stage dependence (16.8% for stage I vs. 90.1% for stage IV)
• Tissue of origin prediction: Correct in approximately 88% of true-positive cases
• Real-world data from over 111,000 tests showed a cancer signal detection rate of 0.91%, with 87% correct tissue of origin prediction⁴.

For prostate cancer specifically, MCED tests have limitations — PSA-based screening remains more sensitive for early-stage prostate cancer than current MCED platforms. However, the concept of a single blood draw screening for many cancers simultaneously is compelling, and these tests are rapidly improving.

Part 28: Urine and Non-Invasive Biomarkers

Researchers are developing even less invasive ways to detect and monitor prostate cancer:

• Urine-based biomarkers: Several urine tests already exist (PCA3, SelectMDx, ExoDx — discussed in Chapter 3), but next-generation urine tests aim to detect cancer mutations, methylation patterns, and protein signatures with greater accuracy.
• Exosome-based diagnostics: Exosomes are tiny vesicles (bubble-like structures) shed by cancer cells into blood and urine. They carry DNA, RNA, and proteins from the parent cancer cell. Analyzing exosomes may provide a "snapshot" of the tumor without a biopsy.¹⁷
• Urinary microbiome profiling: Emerging research suggests that the composition of bacteria in urine may differ between men with and without prostate cancer, potentially offering another non-invasive diagnostic tool.¹⁷ ²¹

Part 29: Patient-Derived Organoids — Testing Drugs on Your Tumor in a Dish

One of the most exciting concepts in personalized medicine is the patient-derived organoid (PDO). Here is how it works:⁴ ⁵ ⁶

1. A small piece of your tumor is obtained from a biopsy or surgery.
2. In the laboratory, cancer cells from that tissue are grown into tiny three-dimensional structures called organoids — essentially miniature versions of your tumor, about the size of a grain of sand.
3. These organoids preserve the genetic, molecular, and structural features of your original cancer.
4. Different drugs are then tested on these organoids to see which ones are most effective at killing your specific cancer cells — before those drugs are given to you.

Think of it as a "dress rehearsal" for your treatment. Instead of trying a drug and waiting weeks to see if it works, doctors could potentially test multiple drugs on your organoid and choose the one most likely to succeed.

Recent studies have shown promising results:⁹ ¹⁰

• Organoids can be successfully grown from prostate biopsy samples, including targeted biopsies of primary tumors.
• Drug screening results from organoids have shown correlation with actual patient outcomes — when the organoid responded to a drug, the patient tended to respond as well.
• A clinical trial is currently testing whether organoid-based drug sensitivity screening can guide treatment decisions in mCRPC patients who have progressed after first-line therapy.¹⁴

Current limitations: Organoid culture takes time (typically 2–4 weeks), success rates vary (50–62% in recent studies), and the organoids do not perfectly replicate the tumor microenvironment — they lack blood vessels, immune cells, and the surrounding tissue that influence how cancer behaves in the body.¹⁰ ¹¹ However, the technology is improving rapidly, and organoid biobanks are being established to accelerate research.⁸ ¹³

Part 30: Genomics and Precision Medicine

The future of prostate cancer treatment is increasingly personalized:

• Whole genome sequencing: Mapping every gene in your cancer to identify all potential targets for therapy — not just the commonly tested genes like BRCA1/2.
• Expanding actionable mutations: Beyond BRCA, researchers are identifying more genes that predict response to specific treatments (ATM, PALB2, CHEK2, CDK12, and others).
• Pharmacogenomics: Tailoring not just which drug to use, but what dose, based on your individual genetic makeup — some people metabolize drugs faster or slower than others.
• Polygenic risk scores: Combining information from hundreds or thousands of genetic variants to estimate an individual's lifetime risk of developing prostate cancer — potentially allowing more targeted screening strategies.

SECTION G: TECHNOLOGY AND ARTIFICIAL INTELLIGENCE

Part 31: AI in Clinical Decision-Making

Artificial intelligence is being integrated into nearly every aspect of prostate cancer care:

• Treatment recommendation systems: AI tools that integrate pathology, imaging, genomic data, and clinical information to suggest optimal treatment strategies.
• Predictive models for side effects: AI algorithms that predict which patients are most likely to experience specific side effects from treatment, allowing for preventive interventions.
• Clinical decision support: Real-time tools that help doctors interpret complex data and make evidence-based decisions at the point of care.

Important limitations: AI systems can inherit biases from the data they are trained on. If training data underrepresents certain racial or ethnic groups, the AI may perform less accurately for those populations. Additionally, many AI tools are "black boxes" — they provide recommendations without fully explaining their reasoning, which can make it difficult for doctors to verify the logic.²⁸ ³⁰

Part 32: AI in Radiation Therapy

Radiation therapy is one of the fields where AI has made the most practical progress:

• Auto-contouring: AI can now draw the outlines of the prostate, bladder, rectum, and other structures on treatment planning scans in seconds — a task that previously took radiation oncologists 30–60 minutes or more. This speeds up treatment planning and improves consistency.
• AI-optimized treatment planning: Algorithms that can generate high-quality radiation treatment plans automatically, reducing planning time and potentially improving plan quality.
• Quality assurance: AI systems that check treatment plans for errors before they are delivered to patients.
• Predictive toxicity models: AI that predicts which patients are at highest risk for side effects based on their anatomy, treatment plan, and clinical characteristics.

Part 33: Digital Twins — Your Virtual Self

Imagine if your doctor could create a computer model of you — your specific cancer, your anatomy, your genetics, your overall health — and then simulate different treatments on this virtual version of you to see which one would work best, before actually treating you. That is the concept of a digital twin.²⁸ ²⁹

A digital twin in oncology is a dynamic, virtual replica of a patient's physiological and pathological state. It integrates multiple types of data — clinical information, genomic profiles, medical imaging, pathology results — to simulate how a tumor might grow and how it might respond to different treatments.²⁸

In uro-oncology specifically, digital twins are emerging as a promising tool for:³⁴

• Personalized treatment selection: Simulating surgery, radiation, or drug therapy outcomes before choosing a treatment
• Radiotherapy optimization: Predicting how the prostate and surrounding organs will move and change during a course of radiation, allowing for more precise treatment delivery³⁷
• Drug development: Testing new drugs on virtual patient populations before conducting expensive clinical trials³⁵
• Survivorship care: Modeling long-term outcomes and side effects to guide follow-up strategies

A software framework called TumorTwin has been developed as an open-source tool for creating patient-specific cancer digital twins, demonstrating the feasibility of simulating tumor growth and treatment response.³³

Where are we now? Digital twin technology in oncology is still largely experimental. Most implementations use limited real-world data, and few have been validated in clinical settings.³² The technology faces challenges including data integration complexity, computational demands, privacy concerns, and the need for robust validation before clinical use.³⁰ ³¹ However, the concept is advancing rapidly, and early applications in radiotherapy planning show particular promise.³⁷

Part 34: Telemedicine and Remote Monitoring

The COVID-19 pandemic accelerated the adoption of telemedicine in cancer care, and it has become a permanent part of prostate cancer management.⁷⁷

What telemedicine can do for prostate cancer patients:

• Virtual follow-up visits: For patients on active surveillance, hormone therapy, or post-treatment monitoring, many routine visits can be conducted by video or phone. A study from Jordan comparing virtual and in-person follow-up visits after prostate radiation found comparable quality-of-life outcomes and significantly better communication scores with virtual visits.⁷⁵
• Remote blood pressure monitoring: Patients on ADT (which can affect cardiovascular health) can monitor blood pressure at home and share results with their care team.
• Home phlebotomy: Blood draws for PSA and other labs can be done at home by a visiting phlebotomist, eliminating a clinic trip.
• Self-injection of medications: Some patients can learn to administer ADT injections or denosumab at home with nurse support via video.

A pilot study at a major cancer center tested an enhanced telehealth program offering all four components (virtual visits, remote BP monitoring, home phlebotomy, and home injections) to prostate cancer patients on ADT. Results showed:⁷³

• Over 75% of patients reported each service was convenient and saved time
• 97% were likely to participate in telehealth visits again
• 100% were likely to participate in home injections again
• Patients found all services to be feasible, acceptable, and appropriate (mean scores above 4.7 out of 5)
• The program received a net promoter score of 79 (considered excellent)

Multidisciplinary virtual clinics have also proven effective. A program offering sequential virtual consultations with a urologist, radiation oncologist, and medical oncologist — all from the patient's home — showed high satisfaction regardless of patient age, no changes in treatment recommendations compared to in-person evaluation, and 100% adherence to NCCN imaging guidelines (compared to only 66% in the traditional in-person cohort).⁸²

Limitations of telemedicine: Not all visits can be virtual — physical examinations, procedures, and treatments requiring clinic infrastructure still need in-person attendance. Additionally, disparities in digital access persist, with lower uptake among patients with limited internet access, lower socioeconomic status, or language barriers.⁷⁷ ⁸¹

SECTION H: OTHER FRONTIERS

Part 35: The Microbiome and Prostate Cancer — Your Gut Bacteria Matter

One of the most surprising areas of prostate cancer research involves the trillions of bacteria living in your gut — your microbiome. Growing evidence suggests that these bacteria influence prostate cancer development, progression, and treatment response.¹⁶ ¹⁷ ²²

How gut bacteria may affect prostate cancer:

• Inflammation: Imbalanced gut bacteria (dysbiosis) can promote chronic inflammation through pathways like NF-κB, which has been linked to cancer development and progression.¹⁶
• Hormone metabolism: Certain gut bacteria can produce or recycle androgens (male hormones) — the very hormones that drive most prostate cancers. This microbial androgen production may contribute to resistance to hormone therapy (ADT).²² ²⁷
• Immune regulation: The gut microbiome shapes the immune system's ability to recognize and fight cancer. Specific bacteria like Akkermansia muciniphila have been associated with better responses to immunotherapy.²³
• Treatment side effects: Radiation therapy can deplete beneficial gut bacteria like Bacteroides, which has been linked to radiation-related bowel inflammation (proctitis).¹⁷

The "gut-prostate axis" is a term researchers use to describe this bidirectional relationship — prostate cancer treatments alter gut bacteria, and gut bacteria influence how well treatments work.¹⁹ ²⁰

Can we use this knowledge? A landmark randomized, double-blind, placebo-controlled trial tested a phytochemical-rich food supplement (containing ginger, cranberry, pomegranate, turmeric, broccoli, and green tea extracts) with or without a probiotic/prebiotic blend in 212 men with PSA-progressing prostate cancer on surveillance:²⁵

• The phytochemical supplement alone significantly slowed PSA progression (rate of PSA rise dropped from 19.6% to 6.2%)
• Adding the probiotic/prebiotic blend produced an even greater effect — PSA actually declined by 20% on average
• Urinary symptoms and erectile function also improved significantly in the probiotic group
• MRI showed disease stability in the vast majority of patients

This was the world's first double-blind randomized trial to demonstrate that improving gut health with pre- and probiotics can slow PSA progression in prostate cancer.²⁵

Bottom line: The microbiome is an exciting and rapidly evolving area of research. While we cannot yet prescribe specific probiotics as cancer treatment, maintaining a healthy gut through diet, fiber, and fermented foods is a reasonable strategy that may complement standard care.

Part 36: Epigenetics and Drug Resistance

One of the greatest challenges in prostate cancer treatment is drug resistance — why do treatments that initially work eventually stop working?

Epigenetics offers part of the answer. Unlike genetic mutations (permanent changes to DNA), epigenetic changes are modifications that turn genes on or off without altering the DNA sequence itself. Think of it like this: if DNA is the hardware of a computer, epigenetics is the software that determines which programs run.

Cancer cells can use epigenetic changes to:

• Turn off genes that make them vulnerable to drugs
• Turn on genes that help them survive treatment
• Adapt to hormone deprivation by finding alternative growth pathways

Epigenetic therapies aim to reverse these changes — essentially reprogramming cancer cells to become sensitive to treatment again. Several approaches are under investigation:

• DNA methylation inhibitors: Drugs that remove the chemical "off switches" from tumor suppressor genes
• Histone deacetylase (HDAC) inhibitors: Drugs that change how DNA is packaged, potentially reactivating silenced genes
• Combination strategies: Using epigenetic drugs alongside hormone therapy or chemotherapy to prevent or overcome resistance

Part 37: CRISPR and Gene Editing — Rewriting the Code of Cancer

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing technology that allows scientists to precisely cut, delete, or modify specific genes in living cells. Think of it as molecular scissors that can edit the "instruction manual" of a cell.⁴⁷

How CRISPR is being used in prostate cancer research:

• Understanding cancer biology: CRISPR allows researchers to systematically turn off individual genes in prostate cancer cells to understand which genes drive cancer growth, metastasis, and drug resistance.⁴⁷ ⁵³
• Targeting the androgen receptor: Researchers have used CRISPR to directly cut and disable the androgen receptor gene in prostate cancer cells, suppressing their growth — including in cells resistant to enzalutamide (a standard hormone therapy).⁴⁸ ⁵²
• Improving CAR-T therapy: CRISPR is being used to engineer more effective immune cells for CAR-T therapy — for example, removing genes that cause T cells to become exhausted, or adding genes that help them survive in the hostile tumor environment.⁵¹ ⁵³
• Identifying drug targets: CRISPR screening has identified "synthetic lethal" interactions — pairs of genes where disabling one makes cancer cells dependent on the other, revealing new drug targets (such as the PARP1 dependency in BRCA-mutated tumors that led to PARP inhibitor development).⁵¹
• Drug delivery: Researchers have developed targeted delivery systems — such as aptamer-liposome carriers — that can deliver CRISPR components specifically to prostate cancer cells expressing PSMA, achieving tumor regression in animal models.⁵⁵

How far away is CRISPR therapy for prostate cancer patients? While CRISPR-engineered T cells have shown remission in some blood cancers, direct CRISPR-based gene therapy for solid tumors like prostate cancer remains in preclinical stages.⁵¹ Significant challenges include:⁴⁹ ⁵⁰

• Delivery: Getting CRISPR components into cancer cells throughout the body is extremely difficult
• Off-target effects: The molecular scissors might cut in unintended locations, potentially causing harm
• Tumor heterogeneity: Not all cancer cells have the same genetic makeup, so editing one gene may not affect all cells
• Ethical considerations: Germline editing (changes that could be passed to future generations) raises profound ethical questions

Bottom line: CRISPR is a powerful research tool that is accelerating our understanding of prostate cancer biology and improving immunotherapy development. Direct CRISPR-based treatment of prostate cancer is likely years to decades away from clinical use, but the technology is advancing rapidly.

Part 38: Clinical Trial Design Innovations

The way clinical trials are designed and conducted is itself evolving:⁶⁰ ⁶²

• Adaptive trials: These trials can change based on early results — for example, if one treatment arm is clearly superior, patients can be reassigned to the better treatment without waiting for the trial to end.
• Basket trials: A single drug is tested across many different cancer types that share the same genetic mutation. For example, pembrolizumab was approved for any MSI-high tumor regardless of where the cancer originated — this was possible because of basket trial design.
• Umbrella trials: Many different drugs are tested within a single cancer type, with patients assigned to specific drugs based on their tumor's genetic profile.
• Platform trials: Continuously running trials that can add new treatment arms and drop ineffective ones over time, without starting a new trial each time.
• Decentralized trials: Some or all trial activities occur outside traditional clinical trial sites — at local clinics, community hospitals, or even patients' homes using telemedicine, home phlebotomy, and remote monitoring.⁶⁰ ⁶³

Decentralized trials are particularly important for improving access. In 2022, 75% of U.S. counties had no active cancer treatment trials.⁶¹ By allowing patients to participate from their local communities, decentralized trials can:⁶² ⁶³

• Reduce travel burden
• Increase enrollment of underrepresented populations
• Make trials accessible to patients in rural areas
• Maintain trial quality while improving convenience

ASCO has published recommendations calling for streamlined regulatory requirements to facilitate decentralized trial adoption, emphasizing that current administrative burdens present critical barriers.⁶²

Part 39: Addressing Disparities Through Research

Prostate cancer does not affect all men equally. African American men are approximately 1.7 times more likely to be diagnosed and 2.1 times more likely to die from prostate cancer compared to white men. Yet historically, clinical trials have not reflected this disparity — minority populations have been significantly underrepresented in the research that shapes treatment guidelines.

Efforts to address this include:

• Mandating diversity in clinical trials: The FDA and NIH are increasingly requiring that clinical trials include diverse populations
• Community-based participatory research: Partnering with community organizations to design and conduct research that addresses the needs of underserved populations
• AI tools validated across populations: Ensuring that AI diagnostic and prognostic tools perform equally well across racial and ethnic groups
• Tele-oncology solutions: Using telemedicine to bring clinical trial access and expert care to underserved and rural communities⁶¹ ⁷²
• Global access initiatives: Working to ensure that advances in prostate cancer treatment — such as PSMA PET imaging and radioligand therapy — become available in low- and middle-income countries, not just wealthy nations

Part 40: How to Evaluate Cancer News and Headlines

As a prostate cancer patient, you will inevitably encounter news stories about "breakthroughs" and "miracle cures." Here is how to evaluate them critically:

Red flags in cancer news:

• "Cures cancer" — no single treatment cures all cancers
• "Works in mice" — most treatments that work in mice fail in humans
• "100% effective" — no treatment works for everyone
• "Doctors don't want you to know" — legitimate treatments are published in medical journals, not hidden
• "Natural cure" — natural does not mean effective or safe

Questions to ask your doctor about new treatments:

1. What phase of research is this treatment in?
2. Has it been tested specifically in prostate cancer?
3. How many patients were studied?
4. What were the side effects?
5. Is there a clinical trial I could join?
6. Would this treatment replace or complement my current treatment?

Reliable sources for research updates:

• Your oncology team — always your first and best resource
• Prostate Cancer Foundation (pcf.org)
• ZERO Cancer (zerocancer.org)
• National Cancer Institute (cancer.gov)
• ClinicalTrials.gov — searchable database of all registered trials
• ASCO Cancer.Net — patient-friendly research updates

Questions to Ask Your Doctor

1. Are there any clinical trials that might be right for me at this stage?
2. Has my tumor been tested for mutations that could match a targeted therapy?
3. Should I get a liquid biopsy or ctDNA test?
4. Is there a role for immunotherapy or theranostics in my case?
5. Are newer radiation techniques (MR-Linac, SBRT) available at this center?
6. Would my cancer benefit from genomic profiling?
7. How do I evaluate news stories about cancer breakthroughs?
8. Can any of my follow-up visits be done by telemedicine?

Myth vs. Fact

• Myth: "Clinical trials are a last resort." → Fact: Many trials are for newly diagnosed patients and offer cutting-edge treatments with close monitoring.
• Myth: "AI will replace my doctor." → Fact: AI assists doctors with pattern recognition and data analysis — it does not replace clinical judgment, empathy, or the doctor-patient relationship.
• Myth: "If a treatment is in the news, it must be available." → Fact: Most reported breakthroughs are years from routine clinical use. The pipeline from laboratory to clinic typically takes 10–15 years.
• Myth: "Theranostics cures everyone." → Fact: Theranostics is a major advance but works best in selected patients with PSMA-positive disease and is not a cure for most.
• Myth: "Gene editing can fix my cancer now." → Fact: CRISPR is a powerful research tool but is years to decades from routine cancer treatment.
• Myth: "Probiotics can treat prostate cancer." → Fact: Early research on the microbiome is promising, but probiotics are not a substitute for proven cancer treatments.

Key Takeaways

1. Research is advancing on every front — radiation, surgery, systemic therapy, theranostics, imaging, pathology, and AI are all evolving rapidly.
2. Theranostics ("see it and treat it") is a uniquely exciting area where prostate cancer leads all of oncology, with next-generation alpha emitters like actinium-225 showing remarkable early results.
3. Liquid biopsies and AI may soon change how prostate cancer is detected, monitored, and treated — potentially catching recurrence earlier than PSA and making pathology more consistent.
4. Clinical trials are available at every stage of disease — from newly diagnosed to advanced — and participating helps both you and future patients.
5. Always discuss emerging therapies with your oncology team before making treatment decisions based on news headlines. Your doctors are your best resource for understanding what is proven, what is promising, and what is premature.

Support Resources

• ClinicalTrials.gov — searchable database of all registered clinical trials
• Prostate Cancer Foundation (pcf.org) — research updates and clinical trial finder
• ZERO Cancer (zerocancer.org) — trial matching service and patient support
• National Cancer Institute (cancer.gov) — comprehensive clinical trial information
• ASCO Cancer.Net — patient-friendly research updates and educational materials
• NCCN Patient Guidelines (nccn.org) — free patient-friendly versions of treatment guidelines

References

1. ¹ FDA drug development process and clinical trial success rates
2. ² Mascia AE et al. Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial. JAMA Oncol 2023
3. ³ FLASH radiotherapy preclinical evidence and technical challenges
4. ⁴ Treatment planning study evaluating FLASH net sparing effect across tumor sites
5. ⁵ Kishan AU et al. MIRAGE phase 3 trial: MRI-guided vs CT-guided SBRT for prostate cancer — 2-year toxicity outcomes
6. ⁶ MRI-guided SBRT 5-year biochemical recurrence-free survival data (150 patients)
7. ⁷ Daily adaptive MRI-guided radiation therapy — frequency of plan adaptation
8. ⁸ Prospective registry of MRI-guided stereotactic reirradiation for locally recurrent prostate cancer
9. ⁹ PACE-B phase 3 trial: 5-year outcomes of SBRT vs conventional radiotherapy
10. ¹⁰ NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
11. ¹¹ PR24 trial and pelvic SBRT investigations
12. ¹² STOMP and ORIOLE trials — pooled analysis of metastasis-directed therapy
13. ¹³ WOLVERINE individual patient data meta-analysis of MDT in oligometastatic prostate cancer
14. ¹⁴ EXTEND trial — intermittent ADT plus MDT outcomes
15. ¹⁵ RADIOSA trial — SBRT with or without ADT in oligorecurrent prostate cancer
16. ¹⁶ Huang J et al. The role of gut microbiome in prostate cancer: current evidence and emerging opportunities. Cancers 2026
17. ¹⁷ Distante A et al. The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment. Prostate Cancer Prostatic Dis 2025
18. ¹⁸ Pembrolizumab FDA-approved indications for MSI-H/dMMR and TMB-H tumors
19. ¹⁹ Xaluritamig first-in-human study in mCRPC (STEAP1 × CD3 bispecific antibody)
20. ²⁰ Xaluritamig + abiraterone combination data in chemotherapy-naïve mCRPC
21. ²¹ Pei X et al. Advances in human microbiome and prostate cancer research. Front Immunol 2025
22. ²² Pernigoni N et al. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol 2023
23. ²³ Bautista J et al. Reprogramming prostate cancer through the microbiome. Front Med 2025
24. ²⁴ Kim SJ et al. Microbiome and prostate cancer: emerging diagnostic and therapeutic opportunities. Pharmaceuticals 2024
25. ²⁵ Thomas R et al. Gut health and prostate cancer: phytochemical-rich food capsule plus probiotic/prebiotic blend RCT. ASCO GU 2025
26. ²⁶ Markowski MC et al. The microbiome and genitourinary cancer: a collaborative review. Eur Urol 2019
27. ²⁷ Lin G et al. Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer. Oncogene 2024
28. ²⁸ Olawade DB et al. Digital twins in oncology: from predictive modelling to personalised treatment strategies. Crit Rev Oncol Hematol 2026
29. ²⁹ Theivendren P et al. Medical digital twin insights: enhancing cancer treatment through generative modeling. Comput Biol Chem 2026
30. ³⁰ Giansanti D, Morelli S. Exploring the potential of digital twins in cancer treatment: a narrative review of reviews. J Clin Med 2025
31. ³¹ Shen S et al. From virtual to reality: innovative practices of digital twins in tumor therapy. J Transl Med 2025
32. ³² Ștefănigă SA et al. Advancing precision oncology with digital and virtual twins: a scoping review. Cancers 2024
33. ³³ Kapteyn MG et al. TumorTwin: a Python framework for patient-specific digital twins in oncology. BMC Med Inform Decis Mak 2026
34. ³⁴ Görtz M et al. Digital twins for personalized treatment in uro-oncology in the era of artificial intelligence. Nat Rev Urol 2025
35. ³⁵ Bouriga R et al. Advances and critical aspects in cancer treatment development using digital twins. Brief Bioinform 2025
36. ³⁶ Padliya T. One patient, two worlds: digital twins for everyday prevention and care. IEEE Pulse 2025
37. ³⁷ Olawade DB et al. Digital twin applications in radiology and radiotherapy. Eur J Radiol 2026
38. ³⁸ Adaptive AI-driven clinical decision-making in oncology through digital twins. ASCO 2025
39. ³⁹ Yehya A et al. Prostate cancer organoids for tumor modeling and drug screening. Methods Mol Biol 2024
40. ⁴⁰ Lin D et al. Establishment and maintenance of patient-derived prostate cancer organoids. J Vis Exp 2025
41. ⁴¹ Pamarthy S, Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer 2021
42. ⁴² Beshiri M et al. Prostate organoids: emerging experimental tools for translational research. J Clin Invest 2023
43. ⁴³ Qian J et al. Patient-derived organoids based on targeted biopsy of primary prostate cancer. Ann Med 2025
44. ⁴⁴ Ali ZB et al. A patient-derived organoid platform from TUR-P samples enables precision drug screening. Cancers 2025
45. ⁴⁵ Organoid-based drug sensitivity screening to guide mCRPC treatment. ASCO GU 2025
46. ⁴⁶ Cantarelli M et al. Unmasking prostate cancer risk factors leveraging organoid technology. Gene 2026
47. ⁴⁷ Tabibian M et al. Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology. Cell Commun Signal 2024
48. ⁴⁸ Ye C et al. Extracellular vesicles-mediated delivery of CRISPR machinery silences androgen receptor in CRPC cells. Mol Ther 2025
49. ⁴⁹ Park J, Kim J. CRISPR/Cas9 technology providing the therapeutic landscape of metastatic prostate cancer. Pharmaceuticals 2024
50. ⁵⁰ Hazafa A et al. CRISPR/Cas9: a powerful genome editing technique for the treatment of cancer cells. Life Sci 2020
51. ⁵¹ Ma Y, Liao Y. CRISPR-mediated cancer therapies: approaches to direct tumor targeting. Crit Rev Oncol Hematol 2026
52. ⁵² Wei C et al. CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Mol Med Rep 2018
53. ⁵³ Wang KC et al. CRISPR/Cas technologies for cancer drug discovery and treatment. Trends Pharmacol Sci 2025
54. ⁵⁴ Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nat Rev Urol 2021
55. ⁵⁵ Zhen S et al. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget 2017
56. ⁵⁶ Patel TH et al. Adoption of decentralized trial elements in cancer clinical trials supporting FDA approvals during COVID-19. Clin Cancer Res 2025
57. ⁵⁷ Morrison JK et al. Building HOPE: operationalizing hybrid decentralized oncology clinical trials. Oncologist 2026
58. ⁵⁸ Thota R et al. Improving access to patient-focused, decentralized clinical trials: an ASCO research statement. J Clin Oncol 2024
59. ⁵⁹ Underhill C et al. Decentralized clinical trials as a new paradigm of trial delivery. JAMA Oncol 2024
60. ⁶⁰ Bisset B et al. Applications and outcomes of telehealth and integrated care in men's health urology. J Med Internet Res 2025
61. ⁶¹ Pilot study of enhanced telehealth program for patients with prostate cancer. ASCO 2025
62. ⁶² Novara G et al. Telehealth in urology: a systematic review. Eur Urol 2020
63. ⁶³ Abaza H et al. Virtual versus in-person visits in prostate cancer: communication and patient-reported outcomes. JCO Glob Oncol 2026
64. ⁶⁴ Multidisciplinary prostate cancer consultation at home: virtual visit platform. ASCO 2023
65. ⁶⁵ Telemedicine in oncology: impact on clinical outcomes, access to care. ASCO 2026
66. ⁶⁶ Chen LW et al. Telehealth use and perceptions among prostate cancer survivors. Cancer Med 2023